Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Clin Cancer Res. 2020 Nov 10;27(3):799–806. doi: 10.1158/1078-0432.CCR-20-2861

Figure 3. MET expression in MET exon 14-altered lung cancers and acquired resistance.

Figure 3.

Figure 3.

(a) MET protein expression by mass spectrometry (SRM-MS). (b) MET expression by immunohistochemistry (IHC). (c) Correlation of MET protein expression between SRM-MS and IHC. (d) MET exon 14 skipping detected by RNA-based anchored multiplex PCR (blue – skipping present; open circle– insufficient tissue). (e) Best response to MET inhibition by IHC expression. (f) Best response to MET inhibition by protein expression (SRM-MS). (g) Progression-free survival in cancers stratified by H-score.